

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | |
|--|--|---|
| 1. Name and Address of Reporting Person* <u>Sanna Bastiano</u> _____ (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE _____ (Street) BOSTON MA 02210 _____ (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC / MA [VRTX]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP, Cell & Genetic Therapies</u> |
| | 3. Date of Earliest Transaction (Month/Day/Year) 05/02/2023 | |
| | 4. If Amendment, Date of Original Filed (Month/Day/Year) | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|----------------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 05/02/2023 | | S ⁽¹⁾ | | 1,411 | D | \$350.32 ⁽²⁾⁽³⁾ | 38,302 | D | |
| Common Stock | 05/02/2023 | | S ⁽¹⁾ | | 42 | D | \$351.65 ⁽²⁾⁽⁴⁾ | 38,260 | D | |
| Common Stock | 05/02/2023 | | S ⁽¹⁾ | | 169 | D | \$353.24 ⁽²⁾⁽⁵⁾ | 38,091 | D | |
| Common Stock | 05/03/2023 | | S ⁽¹⁾ | | 2,053 | D | \$350.44 ⁽²⁾⁽⁶⁾ | 36,038 | D | |
| Common Stock | 05/03/2023 | | S ⁽¹⁾ | | 728 | D | \$351.6 ⁽²⁾⁽⁷⁾ | 35,310 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|--|-----|---|--|--|---|--|
| | | | | Code | V | | (A) | (D) | | | | | |

Explanation of Responses:

- Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.
- Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of \$350.32 (range \$350.00 to \$350.92).
- Open market sales reported on this line occurred at a weighted average price of \$351.65 (range \$351.48 to \$351.80).
- Open market sales reported on this line occurred at a weighted average price of \$353.24 (range \$353.21 to \$353.49).
- Open market sales reported on this line occurred at a weighted average price of \$350.44 (range \$350.00 to \$350.94).
- Open market sales reported on this line occurred at a weighted average price of \$351.60 (range \$351.01 to \$352.00).

Remarks:

/s/ Christiana Stevenson,
Attorney-in-Fact 05/04/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.